Enovis price target lowered to $55 from $62 at Citizens JMP

Citizens JMP lowered the firm’s price target on Enovis (ENOV) to $55 from $62 and keeps an Outperform rating on the shares. Consolidated Q1 results in sales and adjusted EBITDA nearly matched consensus, and updated guidance for 2025 reflects the positive impacts of foreign exchange on the top-line range and the negative impact of tariffs on EPS and adjusted EBITDA, the firm says. The stock’s valuation does not fully capture the benefits and potential upside of the complete integration of the Lima acquisition, Citizens argues.